Bailard’s Repligen RGEN Stock Holding History

Bailard’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,161	Closed	-$535K	–	776
2022 Q4	$535K	Buy	+3,161	New	+$573K	0.02%	387

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bailard's RGEN Position: Q1 2023 in Review

Bailard sold out of Repligen (RGEN) in Q1 2023, closing a stake of 3,161 shares — an estimated $535K sold.

Bailard first reported a position in RGEN in Q4 2022 and held it in 1 quarter. The position peaked at $535K in Q4 2022. 446 funds tracked by Wall St. Rank hold RGEN as of Q1 2023.

Bailard reported no remaining Repligen position as of Q1 2023 after selling out during the quarter.
Bailard sold 3,161 Repligen shares in Q1 2023, an estimated $535K.
Bailard first reported a position in Repligen in Q4 2022 and held it in 1 quarter.
Bailard's Repligen position peaked at $535K in Q4 2022.
446 funds tracked by Wall St. Rank held Repligen as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.